From evidence-based to hope-based medicine? Ethical aspects on conditional market authorization of and early access to new cancer drugs-Reference-Cited by-同舟云学术

From evidence-based to hope-based medicine? Ethical aspects on conditional market authorization of and early access to new cancer drugs

Published:2017-08 Issue: Volume:45 Page:58-63
ISSN:1044-579X
Container-title:Seminars in Cancer Biology
language:en
Short-container-title:Seminars in Cancer Biology

Author:

Sandman Lars,Liliemark Jan

Publisher

Elsevier BV

Subject

Cancer Research

Reference38 articles.

1. Stepwise market approval of new pharmaceuticals. Principle of hope should not displace principle of safety [press release]. GKV Spitzenverband web page: GKV Spitzenverband 2016.

2. Conditional market authorisation;EMA,2017

3. From adaptive licensing to adaptive pathways: delivering a flexible life-span approach to bring new drugs to patients;Eichler;Clin. Pharmacol. Ther.,2015

4. Cancer drugs, survival, and ethics;Wise;BMJ-Br. Med. J.,2016

5. Approvals of drugs with uncertain benefit-risk profiles in Europe;Banzi;Eur. J. Intern. Med.,2015

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Availability and Access to Orphan Drugs for Rare Cancers in Bulgaria: Analysis of Delays and Public Expenditures;Cancers;2024-04-12

2. How aging of the global population is changing oncology;ecancermedicalscience;2021-12-13

3. Oncology drugs and added benefit: insights from 3 European health technology assessment agencies on the role of efficacy endpoints;Journal of Medical Economics;2021-12-06

4. Priority setting in head and neck oncology in low-resource environments;Current Opinion in Otolaryngology & Head & Neck Surgery;2019-06

5. Medical treatment of endometriosis-related pain;Best Practice & Research Clinical Obstetrics & Gynaecology;2018-08